Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 10c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $215.98 +3.92%
EPS Growth %: -22.5%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -22.5%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.30, $0.10 better than the analyst estimate of $4.20. Revenue for the quarter came in at $932.9 million versus the consensus estimate of $902.46 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2022 EPS of $16.70-$17.71, versus the consensus of $17.09. Jazz Pharmaceuticals sees FY2022 revenue of $3.5-3.7 billion, versus the consensus of $3.6 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- enVVeno Medical (NVNO) Misses Q3 EPS by 302c
- Oppenheimer Holdings (OPY) Reports Q3 EPS of $1.81
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
